search
Back to results

Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Comparator: Sitagliptin
Comparator: Placebo
Comparator: Pioglitazone
Metformin
Sponsored by
Merck Sharp & Dohme LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patient has type 2 diabetes mellitus (T2DM) Patient is 18 years of age (or older) Patient is not pregnant or breast-feeding and does not plan to become pregnant for the duration of the study and poststudy follow-up period Exclusion Criteria: Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis Patient required insulin within the prior 8 weeks Patient is on a weight loss program and is not in the maintenance phase Patient started on a weight loss medication (e.g., orlistat or sibutramine) within the prior 8 weeks Patient is on or likely to require treatment with treatment with immunosuppressive agents (e.g., cyclosporin, methotrexate) Patient has cirrhosis, active liver disease (other than fatty liver) or symptomatic gallbladder disease Patient has chronic myopathy, or a progressive neurological or neuromuscular disorder (e.g., multiple sclerosis or polymyositis) Patient has any of the following disorders within the past 6 months: Acute coronary syndrome (e.g., MI or unstable angina), Coronary artery intervention, Stroke or transient ischemic neurological disorder. Patient has new or worsening signs or symptoms of coronary heart disease within the past 3 months Patient has severe peripheral vascular disease Patient has congestive heart failure Patient is HIV positive Patient has a clinically important hematological disorder (e.g., aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia) Patient has a history of neoplastic disease Patient has a history of alcohol or drug abuse within the past 3 years Patient has viral hepatitis (hepatitis B or C)

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Placebo Comparator

    Arm Label

    Sitagliptin 100 mg

    Placebo

    Arm Description

    Sitagliptin 100 mg

    Placebo

    Outcomes

    Primary Outcome Measures

    Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24
    HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent.

    Secondary Outcome Measures

    Change From Baseline in FPG (Fasting Plasma Glucose) at Week 24
    Change from baseline at Week 24 is defined as Week 24 minus Week 0.

    Full Information

    First Posted
    July 2, 2004
    Last Updated
    February 4, 2016
    Sponsor
    Merck Sharp & Dohme LLC
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00086502
    Brief Title
    Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus
    Official Title
    A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Pioglitazone Therapy
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2016
    Overall Recruitment Status
    Completed
    Study Start Date
    June 2004 (undefined)
    Primary Completion Date
    November 2005 (Actual)
    Study Completion Date
    November 2005 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Merck Sharp & Dohme LLC

    4. Oversight

    5. Study Description

    Brief Summary
    The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Diabetes Mellitus, Type 2

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigator
    Allocation
    Randomized
    Enrollment
    353 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Sitagliptin 100 mg
    Arm Type
    Active Comparator
    Arm Description
    Sitagliptin 100 mg
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    Placebo
    Intervention Type
    Drug
    Intervention Name(s)
    Comparator: Sitagliptin
    Other Intervention Name(s)
    Januvia
    Intervention Description
    Sitagliptin 100 mg once daily, from Visit 4 through Visit 8. Day 1 through week 24
    Intervention Type
    Drug
    Intervention Name(s)
    Comparator: Placebo
    Intervention Description
    Placebo (to match Sitagliptin 100 mg) once daily, from Visit 4 through Visit 8. Day 1 through Week 24
    Intervention Type
    Drug
    Intervention Name(s)
    Comparator: Pioglitazone
    Other Intervention Name(s)
    ACTOS
    Intervention Description
    Pioglitazone 30 mg or 45 mg once daily, Visit 2 through Visit 8
    Intervention Type
    Drug
    Intervention Name(s)
    Metformin
    Intervention Description
    Metformin rescue for patients meeting pre-specified glycemic criteria. Metformin 500 mg,once daily, Visit 4 through Visit 8
    Primary Outcome Measure Information:
    Title
    Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24
    Description
    HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent.
    Time Frame
    Baseline and week 24
    Secondary Outcome Measure Information:
    Title
    Change From Baseline in FPG (Fasting Plasma Glucose) at Week 24
    Description
    Change from baseline at Week 24 is defined as Week 24 minus Week 0.
    Time Frame
    Baseline and week 24

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patient has type 2 diabetes mellitus (T2DM) Patient is 18 years of age (or older) Patient is not pregnant or breast-feeding and does not plan to become pregnant for the duration of the study and poststudy follow-up period Exclusion Criteria: Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis Patient required insulin within the prior 8 weeks Patient is on a weight loss program and is not in the maintenance phase Patient started on a weight loss medication (e.g., orlistat or sibutramine) within the prior 8 weeks Patient is on or likely to require treatment with treatment with immunosuppressive agents (e.g., cyclosporin, methotrexate) Patient has cirrhosis, active liver disease (other than fatty liver) or symptomatic gallbladder disease Patient has chronic myopathy, or a progressive neurological or neuromuscular disorder (e.g., multiple sclerosis or polymyositis) Patient has any of the following disorders within the past 6 months: Acute coronary syndrome (e.g., MI or unstable angina), Coronary artery intervention, Stroke or transient ischemic neurological disorder. Patient has new or worsening signs or symptoms of coronary heart disease within the past 3 months Patient has severe peripheral vascular disease Patient has congestive heart failure Patient is HIV positive Patient has a clinically important hematological disorder (e.g., aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia) Patient has a history of neoplastic disease Patient has a history of alcohol or drug abuse within the past 3 years Patient has viral hepatitis (hepatitis B or C)
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Medical Monitor
    Organizational Affiliation
    Merck Sharp & Dohme LLC
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    17157112
    Citation
    Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006 Oct;28(10):1556-68. doi: 10.1016/j.clinthera.2006.10.007.
    Results Reference
    background

    Learn more about this trial

    Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus

    We'll reach out to this number within 24 hrs